2025年全球生命科学行业首席执行官（CEO）展望报告_22页_1mb

KPMG 2025 Global Life Sciences CEO Outlook Summary

Core Content

The KPMG 2025 Global Life Sciences CEO Outlook highlights the evolving landscape of the Life Sciences sector, emphasizing the balance between innovation and efficiency, the increasing role of AI, and the strategic focus on M&A, workforce development, and ESG initiatives. The report is based on a global survey of 110 Life Sciences CEOs, offering insights into their priorities, challenges, and recommendations for future success.

Main Points

Industry Confidence and Growth Expectations

• Confidence in growth is rising, with 83% of Life Sciences CEOs confident in the industry's growth prospects, up from 67% in 2024.
• 55% of CEOs expect earnings growth of more than 2.5% over the next three years.
• 86% of CEOs have a moderate-to-high appetite for M&A, slightly below the cross-sector average of 89%.
• M&A is seen as a tool for unlocking value, with a focus on transformational value rather than just scale or volume.

Technology and AI Integration

• AI is a top priority, with 73% of CEOs planning to allocate 10–20% of their technology budgets to AI.
• 22% expect returns on AI investments within a year, and 65% within one to three years.
• AI is expected to enhance decision-making and data analytics capabilities, with 25% of CEOs reporting such benefits.
• Operational efficiency and productivity are among the top benefits from AI implementation.

Key Challenges

• Integration of AI into organizational processes and systems is a major challenge.
• Supply chain resilience and technological disruption are top concerns.
• Global economic uncertainty is a key pressure on short-term decision-making.
• Cybersecurity is a significant concern, with 84% of CEOs worried about vulnerabilities to cyber-attacks.

Workforce Transformation

• 85% of CEOs believe AI workforce readiness will impact growth objectives.
• Hybrid work models are expected to be the norm, with 73% anticipating most corporate staff to work in hybrid models within three years.
• Retraining and upskilling are key strategies to retain and attract talent, especially among non-digital-native generations.
• Generational gaps are a concern, with differing expectations around work structure, progression, and communication styles.

Sustainability and ESG

• ESG is a strategic imperative, with 57% of CEOs considering it a top priority for the next three years.
• 25% of CEOs integrate the costs and ROI of sustainability initiatives into every major capital investment.
• 40% of CEOs are adopting regionalized sustainability approaches based on market context.
• AI is expected to aid in reducing emissions, improving energy efficiency, and identifying resource efficiency improvements.

Key Recommendations

• Transact to transform: Use M&A strategically to unlock value, either through divestment or acquisition, with a focus on transformational value.
• Focus on supply chain: Ensure supply chains are fit for purpose, integrating suppliers and partners with interoperable data standards and AI-driven governance.
• Lead by example: CEOs should embed AI into operating models and ensure ethics, security, compliance, and trust are prioritized.
• Maximize tech investments: Focus on data accessibility, security, and regulatory compliance by adopting interoperable data standards and AI governance.
• Focus on business challenges: Align AI investments with specific business challenges rather than use cases alone.
• Reshape workforces: Implement intentional and planned AI initiatives with a focus on humans at the center, creating new roles and experiences through change communication and upskilling programs.
• Sharpen focus: Concentrate resources on areas of highest impact to achieve stronger results.
• Apply AI to low-hanging fruit: Use AI to improve energy efficiency, supply chain resilience, and operational performance.

Future Capabilities

The top five most important future capabilities for Life Sciences companies are:

1. Internet of Medical Things (IoMT)
2. Privacy Enhancing Technologies
3. Biomimetic Devices
4. AI in Products and Services
5. Agentic AI/Intelligent Manufacturing

Conclusion

The Life Sciences sector is poised for growth driven by innovation and efficiency, with AI playing a central role. CEOs are adapting their strategies to address market challenges, workforce transformation, and sustainability goals. The report underscores the need for strategic focus, collaborative approaches, and investment in talent and technology to navigate this dynamic environment.

Supporting Data

• 83% of CEOs are confident in the industry's growth prospects.
• 80% have adapted their growth strategies to reflect market challenges.
• 84% are worried about cyber-attacks.
• 73% expect most corporate staff to be in hybrid models.
• 25% of CEOs integrate sustainability costs and ROI into major capital investments.

How KPMG Can Help

KPMG offers multidisciplinary support to Life Sciences organizations, including:

• Deal advisory and transaction support
• AI and technology integration
• Operational transformation
• ESG and sustainability strategy development

KPMG's global network of 4,000 professionals provides practical insights and expertise to help organizations navigate the challenges and opportunities of the sector.